Klaas Dewaele

Dr. Klaas Dewaele

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2020 in Blood
Verified
Journal Article
Open access
PDF file
KDKlaas Dewaele
Klaas Dewaele
RCRowan Claeys
Rowan Claeys
Klaas Dewaele, Rowan Claeys; Hemophagocytic lymphohistiocytosis in SARS-CoV-2 infection, Blood, Volume 135, Issue 25, 18 June 2020, Pages 2323, https://doi.org

4 December 2018 in Acta Clinica Belgica
Verified
Journal Article
Closed access
KDKlaas Dewaele
Klaas Dewaele
JFJohan Frans
Johan Frans
ASAnnick Smismans
Annick Smismans
EHErwin Ho
Erwin Ho
TTTim Tollens
Tim Tollens
Katrien LagrouKatrien Lagrou
Katrien Lagrou
Objective and importance: Candida auris is a relatively new yeast species and an emerging opportunistic pathogen. It was first reported in 2009 in East Asia, as a difficult-to-identify Candida species of uncertain clinical relevance. In recent years, it has appeared globally as a cause of invasive infections, not infrequently eliciting nosocomial outbreaks. Species identification in clinical laboratories has been challenging, as traditional phenotypic and biochemical methods have been generally unreliable. Clinical management is often complicated by multidrug resistance in many isolates. Additionally, C. auris has demonstrated an unusual ability for persistence in the hospital environment and in asymptomatic patients. We present the first Belgian case of C. auris infection along with a brief review of the literature.Clinical presentation: A patient was referred from Kuwait for surgical treatment after a complicated bariatric procedure. Few days after transferral, she developed a catheter-related blood stream infection with C. auris. We obtained a low-confidence identification of C. auris with the Bruker Biotyper MALDI-TOF MS system (Bruker Corporation, Billerica, MA, U.S.A.), and of Candida haemulonii with the Vitek YST identification system, version 7.01 (bioMérieux, Marcy-L’Etoile, France). Definite identification was obtained using Internal Transcribed Spacer (ITS) sequencing. As most C. auris isolates, our strain was resistant to fluconazole, and the patient was eventually treated with catheter removal and anidulafungin therapy. We documented persistence of C. auris clones with acquired echinocandin resistance in our patient up to 18 months after the infection.Conclusion: Clinicians and microbiologists should be aware of this globally emerging yeast, that poses important challenges in identification, treatment and hospital infection control.

5 September 2019 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
KDKlaas Dewaele
Klaas Dewaele
Katrien LagrouKatrien Lagrou
Katrien Lagrou
JFJohan Frans
Johan Frans
MHMarie-Pierre Hayette
Marie-Pierre Hayette
KVKris Vernelen
Kris Vernelen
Candida auris is a difficult-to-identify, emerging yeast and a cause of sustained nosocomial outbreaks. Presently, not much data exist on laboratory preparedness in Europe. To assess the ability of laboratories in Belgium and Luxembourg to detect this species, a blinded C. auris strain was included in the regular proficiency testing rounds organized by the Belgian public health institute, Sciensano. Laboratories were asked to identify and report the isolate as they would in routine clinical practice, as if grown from a blood culture. Of 142 respondents, 82 (57.7%) obtained a correct identification of C. auris. Of 142 respondents, 27 (19.0%) identified the strain as Candida haemulonii. The remaining labs that did not obtain a correct identification (33/142, 23.2%), reported other yeast species (4/33) or failed to obtain a species identification (29/33). To assess awareness about the infection-control implications of the identification, participants were requested to indicate whether referral of this isolate to a reference laboratory was desirable in a clinical context. Over one-third of all respondents (54/142, 38.0%) stated that they would not send the isolate to a reference laboratory, neither for epidemiological reasons nor for identification confirmation or antifungal susceptibility testing. This comprised 41.5% of the laboratories that submitted an identification of C. auris (34/82). Awareness among Belgian microbiologists, therefore, remains inadequate more than two years after C. auris’ emergence in European clinics. Our data confirm high rates of misidentifications with commonly used identification methods. Programs for raising awareness in European hospitals may be warranted.

12 August 2026 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
KDKlaas Dewaele
Klaas Dewaele
CJChristelle Jouego
Christelle Jouego
AAAdina Asim
Adina Asim
LLLies Laenen
Lies Laenen
CMConor Meehan
Conor Meehan
EAEmmanuel André
Emmanuel André
Whole-genome sequencing (WGS) accelerates drug-susceptibility testing (DST) in Mycobacterium tuberculosis (Mtb). Open-access software tools have become widely available, but the sources of real-world performance variability remain uncharacterized. We performed a systematic review and meta-analysis of the performance of open-access, independently validated WGS-based DST prediction tools. Bivariate random-effects meta-analysis was performed for six maintained tools (TBProfiler, Mykrobe, PhyResSE, MTBseq, GenTB, and SAM-TB). Bivariate meta-regression identified covariates associated with performance variation. Thirty-nine studies comprising 144,623 genomes were included. For the two most extensively validated tools, TBProfiler and Mykrobe, pooled rifampicin sensitivity was 95.4% (95% CI: 93.5–96.7) and 93.7% (92.0–95.1), with a specificity of 97.3% (95.7–98.3) and 97.0% (94.8–98.3), respectively. For isoniazid, the sensitivity was 92.0% (90.4–93.3) and 88.2% (85.5–90.4) and specificity 97.3% (96.0–98.2) and 97.5% (95.8–98.5). For ethambutol, the specificity was heterogeneous across tools (86.5%–95.4%); for pyrazinamide, the sensitivity varied widely (49.9%–80.6%). For fluoroquinolones, both sensitivity and specificity approached 90%, with heterogeneity. For newer agents, data scarcity precluded meaningful assessment. Meta-regression identified rifampicin resistance prevalence as the dominant predictor of decreased specificity across first-line drugs (β −1.5 to −3.6 on logit scale, false discovery rate [FDR] q < 0.05), while lineage composition effects were small and confounded. Current open-access WGS prediction tools achieve clinically useful accuracy as rule-out tests for rifampicin, isoniazid, and fluoroquinolone resistance. Predictive performance for second-line drugs is limited by data scarcity. Methodological limitations, including lineage bias, data leakage, and selective sampling, may undermine the tools’ generalizability across diverse global tuberculosis populations. IMPORTANCE: Tuberculosis remains a leading infectious disease killer worldwide. Whole-genome sequencing (WGS) of Mycobacterium tuberculosis offers the potential to rapidly predict drug resistance as a one-stop test, but the accuracy of the software tools used to interpret sequencing results has been inconsistently reported. This meta-analysis leverages the heterogeneity across 39 studies and 144,623 genomes to identify factors that drive inconsistencies in reported performance, providing context-specific guidance for clinical adoption. We show that most tools perform adequately as rule-out tests for resistance to the most important first- and second-line drugs but fall short of specificity targets. Importantly, we identify that the local burden of drug resistance in a study population is the dominant factor driving inconsistencies between reported performance estimates. These findings provide guidance for laboratories considering adopting sequencing-based resistance testing and specify priorities for future tool development and validation.

1 September 2026 in Microbiology Spectrum
Verified
Journal Article
Open access
FMFaridath Massou
Faridath Massou
KDKlaas Dewaele
Klaas Dewaele
AGAnderson Gnamy
Anderson Gnamy
RBRamata Balde
Ramata Balde
WMWim Mulders
Wim Mulders
LRLeen Rigouts
Leen Rigouts
The interpretation of genetic variants’ association (or not) with phenotypic resistance to newly introduced and repurposed antituberculosis drugs remains challenging, as many mutations detected by whole-genome sequencing (WGS) are classified as of uncertain significance (group 3) or not associated with resistance-interim (group 4) by the World Health Organization (WHO) mutation catalog v2. We evaluated the phenotypic impact of such variants on minimum inhibitory concentrations (MICs) for bedaquiline (BDQ), clofazimine (CFZ), delamanid (DLM), and pretomanid (PA) in Mycobacterium tuberculosis complex isolates from the multi-country DIAMA cohort in sub-Saharan Africa (SSA), which recruited RR/RS-TB patients naïve to these drugs. Among 1,475 isolates with available WGS data, 163 variants met eligibility criteria; due to viable strain unavailability, 89 isolates carrying 29 unique BDQ/CFZ-related and 60 unique DLM/PA-related variants were tested for MIC determination using broth microdilution. Additional structural modeling was performed to explore potential effects of amino-acid substitutions on protein stability. Among BDQ/CFZ-related variants, MICs above the critical concentrations (CCs) were consistently associated with mmpR5 variants, whereas variants in atpE , pepQ , and Rv1979c were not. DLM/PA variants ( ddn, fbiA–D, and fgd1 ) were frequently detected as non-fixed populations, yet rarely yielding MIC values above the CC. Predicted structural destabilization showed no consistent association with MIC values or variant fixation status. Under the conditions tested, phenotypic resistance was not detected for most group 3 and 4 variants detected by WGS. Our data provide evidence from SSA to support improved interpretation of resistance-associated mutations for new and repurposed antituberculosis drugs. IMPORTANCE: Whole-genome sequencing increasingly detects Mycobacterium tuberculosis complex mutations classified by the World Health Organization (WHO) mutation catalog v2 as group 3 variants of uncertain significance or group 4 variants not associated with resistance-interim, limiting reliable prediction of resistance to new and repurposed antituberculosis drugs. By generating minimum inhibitory concentration (MIC) data for such variants identified in a multi-country sub-Saharan African cohort, this study provides phenotypic evidence to support future refinement and expansion of the WHO mutation catalog v2. Notably, mmpR5 variants associated with elevated bedaquiline/clofazimine MICs were identified in eight isolates, suggesting that some patients in this cohort may have harbored pre-existing resistance-associated variants yet remained potentially eligible for bedaquiline-containing regimens. These findings contribute to improving the interpretation of genomic resistance data and strengthening surveillance of resistance to bedaquiline, clofazimine, delamanid, and pretomanid.

2 November 2026 in Microbiology Spectrum
Verified
Journal Article
Open access
CRCéline Rens
Céline Rens
PCPatricia Constant
Patricia Constant
KDKlaas Dewaele
Klaas Dewaele
RBRamata Balde
Ramata Balde
KSKarine Soetaert
Karine Soetaert
Véronique FontaineVéronique Fontaine
Véronique Fontaine
Tuberculosis remains the leading cause of death by a single infectious agent, Mycobacterium tuberculosis , in the world. To tackle this disease, efforts are conducted, among others, to improve diagnosis coverage and treatment access, to develop an improved vaccine, and to find new antituberculous drugs or drug regimens. In vitro , bacteria usually tend to lose virulence factors to improve their fitness, mostly observed by an increased growth. This is also the case for M. tuberculosis strains and clinical isolates prone to lose phthiocerol dimycocerosates in the upper leaflet of their mycomembrane. This loss affects the cell wall integrity, as observed by an increased antimycobacterial activity of vancomycin, providing a potential bias in drug susceptibility testing. Here, we showed that M. tuberculosis culture conditions, such as a single subculture on 7H11 supplemented with oleic acid–albumin–dextrose–catalase, can restore vancomycin resistance and cell wall integrity but can also impact routine drug susceptibility assay by broth microdilution. IMPORTANCE: Vancomycin susceptibility testing can identify Mycobacterium tuberculosis subcultures with compromised cell wall integrity due to phthiocerol dimycocerosates loss. A single pre-culture on potato-Sauton medium or on 7H11 supplemented with oleic acid–albumin–dextrose–catalase can restore cell wall integrity. This study underscores the importance of standardized culture protocols for reliable M. tuberculosis drug susceptibility testing.